America's pet owners are still buying food, litter and flea pills like clockwork. What they are cutting back on is the trip to the vet. That split has been building for several quarters, and it now shows up clearly in company filings and in government price data.
For investors, the pet economy is no longer one trade. Recurring supplies are holding up, while some of the pricier medicines are losing ground. For households, especially empty nesters and retirees whose dogs and cats are getting older, the gap between a cheap bag of food and an expensive clinic bill is getting wider.
- Chewy filings: fiscal second-quarter net sales rose 7.3% to $3.33 billion, Autoship subscription sales rose 9.3% to $2.82 billion, and Autoship reached 84.6% of total sales, with 21.7 million active customers.
- Zoetis filings: second-quarter U.S. companion animal product sales fell 11% to $1.04 billion on lower clinic visits and pet owner price sensitivity, and the company cut its 2026 revenue outlook to $9.12 billion to $9.32 billion.
- IDEXX filings: U.S. same-store veterinary clinic visits fell an estimated 1.3% in the second quarter, led by weaker wellness visits, yet the company's recurring diagnostics revenue grew 11% to $975 million and it raised its 2026 profit outlook.
- Bureau of Labor Statistics CPI data: veterinarian services prices rose 4.6% in the 12 months through September, compared with 1.5% for pet food and treats, while PLMA and Circana data show pet care led all store-brand departments in unit growth.
The food bowl is on autopilot
Chewy is the cleanest window into what pet owners buy every month. The online retailer reported fiscal second-quarter net sales of $3.33 billion, up 7.3% from a year earlier, or 5.7% excluding its SmartPak and Modern Animal acquisitions.
The key number is Autoship, Chewy's subscription program that ships food and supplies on a set schedule. Autoship customer sales grew 9.3% to $2.82 billion, faster than the company as a whole. Autoship now makes up 84.6% of Chewy's sales, up from 83.0% a year earlier.
Active customers rose 3.8% to 21.7 million, and net sales per active customer reached $602. Adjusted EBITDA margin improved by 0.9 percentage point to 6.8%, and management raised its full-year revenue and profitability outlook. Management also said premium upgrades and discretionary add-ons stayed under pressure, which tells you shoppers are buying the basics and skipping the extras.
That is the investment case for recurring pet consumables in one paragraph. A dog eats every day whether the economy is strong or weak. A business that locks in those orders on a subscription can grow steadily even when households feel squeezed.
The vet visit is where owners are pulling back
The other side of the pet economy looks very different. Zoetis, the leading animal health company, reported flat second-quarter revenue of about $2.47 billion. Its U.S. companion animal product sales fell 11% to $1.04 billion.
Management pointed to three causes: fewer clinic visits, pet owner price sensitivity and heavier competition in key categories. The company's key dermatology franchise for itchy dogs fell 16% globally, and generic competition hit two older brands. Zoetis cut its full-year 2026 revenue guidance to $9.12 billion to $9.32 billion, which works out to an organic operational decline of 1% to 3%. Adjusted earnings guidance moved to $6.15 to $6.25 per share.
IDEXX Laboratories, the leader in veterinary diagnostics, sees the same traffic trend from inside the clinic. It estimated that U.S. same-store clinical visits fell 1.3% in the second quarter. Wellness visits, the routine annual checkups, were the main drag, while sick-pet visits grew modestly. IDEXX told investors it expects visits to keep falling by about 1.5% in the second half of the year.
The government's price data helps explain why. In the September Consumer Price Index, veterinarian services prices were up 4.6% from a year earlier. Pet food and treats were up only 1.5%. When the clinic bill keeps rising faster than the food bill, owners start stretching the time between checkups.
Why fewer visits did not hurt every company
Here is the twist for investors. Fewer visits did not mean less revenue for IDEXX. Its recurring diagnostics revenue grew 11% to $975 million in the quarter, and U.S. recurring diagnostics revenue grew about 10%. That is roughly 11 percentage points faster than the decline in clinic visits.
The reason is that each visit is getting more intense. Vets are running more blood work, urine tests and fecal panels per patient, often on in-clinic analyzers that IDEXX sells and then supplies with tests. IDEXX placed more than 1,600 of its newest inVue Dx analyzers in the quarter, pushing that installed base past 9,000 machines. The company also said it continues to see visit growth in pets five years and older, which is the aging-pet trend showing up in the data.
IDEXX raised its 2026 earnings outlook to $14.69 to $14.94 per share and narrowed revenue guidance to $4.70 billion to $4.745 billion. Its second-quarter operating margin improved by 1.4 percentage points.
So the clinic economy is splitting too. When owners visit less often but come in with an older or sicker pet, the diagnostic test becomes more valuable, while elective or premium treatments are easier to delay or swap for a cheaper option.
Store brands are moving into the pet aisle
Grocery data adds one more piece. The Private Label Manufacturers Association, using Circana data, reported that store brands reached a record 23.8% share of unit sales in the first half of 2026. Among all departments Circana tracks, pet care was the leader in store-brand unit growth, up 4.8% over the 52 weeks ending in mid-June.
That matches what Chewy and Zoetis describe. Owners are not abandoning their pets. They are trading down on the parts of the bill where a cheaper option feels safe, and holding the line on the parts where it does not.
What this means for investors
The pet sector used to trade as one big premiumization story: people treat pets like family, so they will pay up for everything. The filings now point to a more selective consumer, and that changes which business models look strongest.
Recurring consumables look the most durable. Subscription-heavy sellers benefit from habits, not splurges. The risk is margin, not demand, since store brands and price competition can pressure what each bag of food earns.
Diagnostics with a razor-and-blade model have shown they can grow even when traffic shrinks, because revenue follows tests per visit and the installed base of analyzers. The risk is that a long decline in visits eventually catches up with test volume, so the visit trend is worth tracking every quarter.
Branded pet medicines are where the pressure is sharpest. Zoetis still has a large portfolio, a strong livestock business that grew 23% in the U.S. last quarter, and a pipeline it says includes more than 12 potential blockbusters. But price-sensitive owners, new competitors and generics are a real headwind for the companion animal side, and the guidance cut shows management is not assuming a quick rebound.
The near-term calendar gives investors two check-ins. IDEXX is scheduled to report third-quarter results on Nov. 2, and Zoetis is scheduled to report on Nov. 5. The questions that matter most: Are U.S. clinic visits still falling around 1.5%, or stabilizing? Is diagnostics revenue still growing far faster than visits? And is Zoetis seeing any recovery in U.S. dermatology and parasite products, or is price competition still spreading?
For dividend-focused and long-horizon investors, the lesson is to separate the pieces. A recurring supply business, a diagnostics leader and a branded drug maker can all be called "pet stocks," but right now they are telling three different stories about the same consumer.
What this means for your household
Tens of millions of U.S. households own a pet, and older pets cost more to keep healthy. If your dog or cat is past middle age, the trends above are a budgeting signal, not just an investing one.
First, do not skip the annual checkup to save money on an older pet. Vets and diagnostics companies both note that pets five and older are driving visit growth for a reason. Catching kidney disease, dental problems or arthritis early is usually cheaper than treating an emergency.
Second, ask for prices before treatment. Clinics are often willing to explain which tests are essential and which can wait. Prescription costs can also vary widely between the clinic, online pet pharmacies and big-box retailers, so it pays to compare.
Third, consider store-brand food and supplies where your vet agrees it is safe. The grocery data shows many owners are already doing this. Saving on the daily items can free up room in the budget for the occasional large clinic bill.
Fourth, if you are weighing pet insurance or a clinic wellness plan, read the fine print on age limits, pre-existing conditions and annual caps. These products tend to cost more as pets age, so the math is different for a 10-year-old dog than for a puppy.
The bottom line: pet owners are protecting the food bowl and trimming the vet bill. That split is helping subscription sellers and diagnostics makers while squeezing branded pet medicines. Watch the IDEXX and Zoetis reports in early November to see whether the visit slump is bottoming out or still spreading.
This article is for informational purposes only and is not financial advice. Do your own research or consult a licensed financial professional before making investment decisions.
